Study #2024-1939
A phase 2 open-label, multicenter study to evaluate efficacy and safety of ZN-c3 in subjects with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer
MD Anderson Study Status
Enrolling
Treatment Agent
azenosertib
Description
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determined by central review using the Sponsor's investigational clinical trial assay.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Study phase:
Phase II
Physician name:
Shannon Westin
Department:
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.